Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- gilteritinib
- Promacta (eltrombopag)
Interactions between your drugs
eltrombopag gilteritinib
Applies to: Promacta (eltrombopag), gilteritinib
Gilteritinib may increase the blood levels and effects of eltrombopag. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
eltrombopag food
Applies to: Promacta (eltrombopag)
Food may reduce the absorption and blood levels of eltrombopag. In addition, minerals such as aluminum, calcium, iron, magnesium, and zinc can also interfere with eltrombopag absorption into the bloodstream, which may make the medication less effective in treating your condition. You should take eltrombopag on an empty stomach one hour before or two hours after a meal. Eltrombopag should also be taken at least 2 hours before or 4 hours after products like antacids, mineral supplements, dairy products, and fortified juices. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Revuforj
Revuforj is used to treat acute leukemia with a lysine methyltransferase 2A gene translocation ...
Xospata
Xospata (gilteritinib) is used to treat acute myeloid leukemia (AML) with a FLT3 mutation. Xospata ...
Vanflyta
Vanflyta (quizartinib) is an oral targeted treatment called a kinase inhibitor that may be used to ...
Oncovin
Oncovin is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.